COVAX: The estimated net profit for 2024 is 190-270 million yuan, a year-on-year decrease of 68.65%-77.94%.

On January 22, Golden Ten Data reported that Kangtai Biological released its performance forecast for 2024, with an expected net profit attributable to shareholders of the listed company of 190 million to 270 million yuan, a year-on-year decrease of 68.65% to 77.94%. During the reporting period, the company’s operating income decreased to a certain extent compared to the same period last year due to market competition, inventory reduction, and other factors. In addition, the increase in depreciation expenses of fixed assets, increase in asset impairment, and termination of the implementation of the 2023 stock incentive plan accelerated the exercise of rights, resulting in a decrease in net profit for 2024 compared to the same period last year. The impact of non-recurring gains and losses on net profit is estimated to be approximately -20 million to -15 million yuan.